Network pharmacology approach and experimental verification of Manzufei decoction in the treatment of chronic obstructive pulmonary disease
Abstract
Manzufei decoction (MZFD) effectively treats COPD, but its mechanisms are unclear. Combining network pharmacology and experimental validation, we identified 168 bioactive components in MZFD and 265 potential targets. Network analysis pinpointed 4 core compounds. Comparing 1167 COPD-related targets revealed 114 overlapping therapeutic targets. Enrichment analysis implicated key pathways, notably AKT signaling. Molecular docking confirmed strong binding of quercetin to AKT and MUC5AC. Animal studies demonstrated that MZFD inhibits AKT signaling pathway activation, reduces MUC5AC protein expression in lung tissue and lung inflammation, thereby alleviating lung injury in AECOPD model rats.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.